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In 1980 Mark Ptashne published a
review entitled How λ repressor and
Cro work followed by another, in
1988, called How eukaryotic
transcriptional activators work. The
bold — almost, some might feel,
naïve — ambition these titles betray
is unashamedly the author’s: to
generate a coherent picture of how
genes are switched on and off.
Mark Ptashne’s approach has
always been transparent. During
group meetings he often responded
to some piece of data or other by
saying that it was fine, but that if one
wanted to learn the truth, one had to
do the right experiment, and that one
couldn’t know what that was unless
one had a very clear idea to test of
how one thought the world worked.
Or he might recall Emerson: “our job
is to turn fact into truth.” Few pursue
this approach as rigorously as Ptashne
— and even fewer as successfully.
But then he seeks to understand his
golf swing in much the same way:
models are built, tested, adhered to,
or discarded. Indeed, nowadays he
rarely indulges in an actual game,
seeing that as an over-elaboration, a
murkying of the waters in his quest
to understand how his golf swing —
and hence, in principle, golf itself —
works.
Although Ptashne respects those
who can move from one scientific
problem to another, he himself is
driven by an unrelenting passion to
understand with complete clarity a
single problem. This pursuit has
provided us with the conceptual
framework in which we understand
how proteins bind to specific sites on
DNA and effect transcription of
nearby genes. Last September, he
was awarded The Lasker Prize (see
http://www.laskerfoundation.com) for this
contribution, which began more than
30 years ago with the isolation of the
bacteriophage λ repressor.
As an undergraduate at Reed
College, Oregon, Ptashne read the
classic Jacob and Monod paper on
the lac operon and was at once
mesmerized by thoughts of finding a
repressor. But when he arrived at
Harvard in 1961, Matt Meselson and
Jim Watson persuaded him that
before he could go after a repressor
he should attempt something a little
less ambitious and earn a
PhD. This turned out to be
good advice; he learned λ genetics,
knowledge that was to prove vital in
designing the scheme that finally
delivered the repressor. That success
came, however, only after a further
two years of fevered and all-
consuming experimental mayhem,
during which one bizarre scheme
after another failed. This was the
period of the well-documented race
with Wally Gilbert who, in a lab just
a few floors below, was searching for
lac repressor. By all accounts the
competition was fierce but
communication was open, and in the
end they both succeeded.
It took the next 15 years or so to
elucidate how λ repressor works, and
how its action underlies the phage’s
ability to choose between two
developmental pathways. This work
was summarized in Ptashne’s classic
1986 book, A Genetic Switch. Simply
stated, repressor molecules normally
bind two adjacent sites on DNA and,
by touching each other, stabilize
their binding to DNA — an example
of co-operative binding.
When bound to DNA, λ repressor
overlaps one promoter, excluding
RNA polymerase and inhibiting
transcription. But it transpired that
the repressor can activate as well as
repress transcription; at a second,
adjacent promoter, repressor touches
polymerase, stabilizing polymerase
binding and activating transcription.
The combination of biochemical
and genetic approaches which led to
this description of how λ repressor
stimulates and represses
transcription remains a tour de force
in modern biology. But it was not
clear that it could explain how genes
are controlled in eukaryotes. In
facing up to this
challenge the focus of
the lab gradually
shifted, from the
early 1980s, away
from λ and towards
the yeast activator
GAL4. And in a series
of bold and novel
experiments it was
demonstrated that no
new principles were required to
explain activation by GAL4. Indeed,
it now seems clear from the work of
many labs that in typical eukaryotic
activators activation is mediated by
direct protein–protein interactions
between the DNA-bound activator
and the transcription machinery, the
intervening DNA looping out where
necessary. These findings
vindicated Ptashne’s approach of
focusing so exhaustively on a
tractable system.
Ptashne has recently set up a new
lab at the Sloane Kettering Institute
in New York, a move reflecting his
continued appetite for research. But
his career hasn’t been restricted to
research. In 1980 he and Tom
Maniatis (a former post-doc, but by
then a fellow faculty member at
Harvard) founded a biotechnology
company called Genetics Institute.
Although he is no longer actively
involved in this company, getting it
established brought Ptashne
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considerable satisfaction and did him
no harm financially.
It is often difficult to reconcile
Ptashne’s achievements with the
chaotic way he appears to live life.
Constantly in the grip of burning
enthusiasms (or, as he sees it, on a
quest for self-improvement) he paces
about, flitting from one issue to
another, unselfconsciously phoning
anyone in the world he believes can
teach him something new, asking
basic questions, rightly unconcerned
that these may sometimes look
naive. His directness can strike some
as aggressive and over-bearing, but
that is to underestimate the essential
role of humour in so much of what he
does. To those who know him it is
clear his motives aren’t malicious or
cynical — it’s more that his fidgety
inquisitiveness leaves him oblivious
to other considerations, and
mystified by the inconvenience and
offense his actions sometimes cause.
The speed and intensity with
which he descends on things can
result in unrealistic expectations.
Typically he might rent eight or nine
videos for a single evening (and still
expect to be in bed by 11pm), or
take a party out to dinner, cause
havoc rearranging restaurant tables
and, just as everyone’s settling,
decide that there’s somewhere better
they must go at once. During one
week spent in London with his new
wife Lucy, they went to the theatre
every night, leaving halfway through
all but one play — not because they
were bad, but because they were not
distracting enough to make Mark
forget the other things he wanted to
do and see. Fleeting obsessions are
numerous, as, for example, when
tropical fish tanks took over his
kitchen and then the lab tea room,
where they monopolized his
attention during seminars when
dimmed lighting set off the in-tank
illumination to dazzling effect.
But this hectic persona conceals a
more disciplined and focused nature.
This is, of course, most apparent in
his science, but also in other long-
term interests, including not only his
golf (swing), but his art collection
(Matisse and Hoffman are
favourites), the writings of Nietzsche,
and — most infamously — his violin
playing. According to the well-known
English violinists Manny Hurwitz
and Adrian Levine, this has
improved remarkably in the past few
years, and both now consider him, for
an amateur, quite exceptional.
He has owned several fine
violins; indeed his passion for them
predates his ability to afford them,
his first Stradivarius being purchased
only with the aid of an elaborate
mortgage scheme. Now he owns the
Wilmotte Stradivarius and the
Guarnerius Del Gesu, known as The
Plowden. Purchasing the latter was a
typically Ptashne affair. A London
dealer who had known him for many
years tracked Ptashne down to a
hotel in Sweden with news that this
treasured violin might become
available. He at once set off for New
York, and on arriving dashed to the
apartment of the owner’s lawyer
where, falling hopelessly in love
with the instrument, he remained
until, a few days later, the deal was
done. The price required him to sell
many possessions, but he’s never
regretted it and this is the violin on
which he practices for two hours
almost every day.
But perhaps most revealing was
his attitude towards the skit put on
by graduate students in the
biochemistry department at Harvard
every Christmas, in which the faculty
is routinely roasted. While other
members of staff understandably
feared ridicule, Ptashne’s chief
concern was that he might be
overlooked. I bumped into him just
after one skit several years ago in
which a story involving him, a
photocopier and a departmental
secretary had been aired. He seemed
dejected, complaining the story was
old and already well known. There
was, he claimed, a lot of newer and
better material they could have used. 
Alexander Gann was a post-doc with Mark
Ptashne and is now in the Division of
Biological Sciences, Lancaster University, UK.
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Geneva Biomedical
Research Institute
What is it famous for? GBRI hit the
news last October when its owner,
the pharmaceuticals giant Glaxo
Wellcome, unexpectedly announced
plans to close the Institute in April,
making up to 170 staff redundant.
What does the institute do? Mostly
basic research into disease
mechanisms at the molecular level,
but it also has sophisticated
automated screening systems for
detecting potential drugs. It’s one of
the most productive molecular
biology centres in Europe,
generating more than 400 papers and
15 patents over the past five years.
Why did Glaxo Wellcome lose interest?
Glaxo bought GBRI as a going
concern from Biogen in 1987, when
molecular biology was still almost a
separate discipline. Now that
molecular techniques are routinely
used throughout its empire, Glaxo
Wellcome says it no longer needs a
separate molecular research center.
So is that it for GBRI? Staff at GBRI
have been looking for a way of
keeping the Institute going. Ideas
included carving it up into several
biotech start-up companies, but now
it seems that the Swiss company
Ares-Serono has snapped it up whole.
Details are still being hammered out,
but the acquisition will probably be
completed early this year.
What does Ares-Serono do? It is a
research-based biotech company that
started in the late 1970s. It employs
more than 4000 people worldwide,
and is valued at 8.9 billion Swiss
francs (US$ 6.25 billion). It is best
known for fertility treatment drugs —
its follicle stimulating hormone
product has about 70% of the market.
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